Cancer advocate Sarah Wise Miller, a member of the Kidney Cancer Association’s governing board, recently participated in the evaluation of research applications submitted to the Peer Reviewed Cancer Research Program (PRCRP) sponsored by the Department of Defense. Ms. Wise was nominated for participation in the program by the Association.
Uplifting Athletes and PSU football team raise funds for kidney research through the annual Lift for Life event, held in State College, PA. In this video, Dr. David McDermott explains the importance of the Kidney Cancer SPORE.
In the search for biomarkers of disease using proteomics techniques, many samples need to be analysed in order to validate the results and confirm the special significance of particular peptides or proteins. Apart from the common biological fluids like plasma and urine, tissue is another highly prized source with the advantage that many hospitals store archived tissue along with the relevant patient histories.
The Kidney Cancer Association’s vice president for public affairs, Carrie Konosky, is in Happy Valley, PA, this weekend to receive funds from the Penn State Chapter of Uplifting Athletes.
Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma
The aims of this study were to quantify and contrast patient preferences between second-line advanced renal cell carcinoma (RCC) medication profiles and their associated benefits and toxicities, and to help frame the doctor-patient discussion about selecting appropriate RCC therapies.
Since the mid-1990s, black Americans have had a higher incidence of renal cell carcinoma, the most common form of kidney cancer, than white Americans. Research also suggests that there are racial disparities in the survival of patients with renal cell carcinoma, with black patients dying earlier than whites.
Hornbuckle, known as the “Soul Diva of the Northwest,” was diagnosed with kidney cancer in August. She's currently undergoing chemotherapy, but keeping a positive attitude.
Regardless of patient and tumor characteristics or surgical treatment, white patients with kidney cancer consistently have a survival advantage over black patients.
The future for kidney cancer patients could be bleak, if this Wall Street Journal op-ed's conclusions are accurate.
There were more than 250 generic drug shortages in 2011 compared with 58 in 2004, thanks largely to the Medicare Modernization Act.